[1]
|
Maruna, P., Nedelnikova, K. and Gürlich, R. (2000) Phy- siology and genetics of procalcitonin. Physiol Research, 49, S57-S61.
|
[2]
|
Meisner, M. (2002) Pathobiochemistry and clinical use of procalcitonin. Clinical Chemica Acta, 323, 17-29.
doi:10.1016/S0009-8981(02)00101-8
|
[3]
|
Dandona, P., Nix, D., Wilson, M.F., et al. (1994) Procal- citonin increase after endotoxin injection in normal sub- jects. The Journal of Clinical Endocrinology & Metabo- lism, 79, 1605-1608.
doi:10.1210/jc.79.6.1605
|
[4]
|
Gabay, C. and Kushner, I. (1999) Acute-phase proteins and other systemic responses to inflammation. The New England Journal of Medicine, 340, 448-454.
doi:10.1056/NEJM199902113400607
|
[5]
|
Assicot, M., Gendrel, D., et al. (1993) High serum pro- calcitonin cencentration in patients with sepsis and infec- tion. Lancet, 341, 515-518.
|
[6]
|
Schneider, H.-G. and Lam, Q.T. (2007) Procalcitonin for the clinical laboratory, a review. Pathology, 39, 383-390.
doi:10.1080/00313020701444564
|
[7]
|
Simon, L., Gauvin, F., et al. (2004) Serum procalcitonin and C-reactive protein levels as markers of bacterial in- fection, a systematic review and meta-analysis. Clinical Infectious Diseases, 39, 206-217. doi:10.1086/421997
|
[8]
|
Tang, B. and Eslick, G. (2007) Accuracy of procalcitonin for sepsis diagnosed in the critically ill patients, syste- matic review and meta-analysis. The Lancet Infectious Diseases, 7, 210-217.
doi:10.1016/S1473-3099(07)70052-X
|
[9]
|
Al-Nawas, B. and Shah, P.M. (1996) Procalcitonin in patients with and without immunosuppression and sepsis. Infection, 24, 30-32. doi:10.1007/BF01713044
|
[10]
|
Marti, F. and Cullen, M.H. (2009) Management of febrile neutropenia, ESMO clinical recommendations. Annals of Oncology, 20, 166-169. doi:10.1093/annonc/mdp163
|
[11]
|
Schwenkglenks, M., Jackish, C., Constenla, M., et al. (2006) Neutropenic event risk and impaired chemothe- rapy delivery in 6 european audits of breast cancer treat- ment. Support Care Cancer, 14, 901-909.
doi:10.1007/s00520-006-0034-9
|
[12]
|
Chang, J. (2000) Chemotherapy dose reduction and delay in clinical practice. Evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. European Journal of Cancer, 36, S11-S14.
doi:10.1016/S0959-8049(99)00259-2
|
[13]
|
Elting, L.S., Rubenstein, E.B., et al. (1997) Outcomes of bacteremia in patients with cancer and neutropenia, ob- servations from two decades of epidemiological and cli- nical trials. Clinical Infectious Diseases, 25, 247-59.
doi:10.1086/514550
|
[14]
|
Schüttrumpf, S., Binder, L., et al. (2003) Procalcitonin, a useful discriminator between febrile conditions of diffe- rent origin in hemato-oncological patients. Annals of He- matology, 82, 98-103.
|
[15]
|
Rintala, E. (1994) Incidence and clinical significance of positive blood cultures in febrile episodes of patients with hematological malignancies. Scandinavian Journal of In- fectious Diseases, 26, 77-84.
doi:10.3109/00365549409008594
|
[16]
|
Kim, D.Y., Lee, Y.-S., et al. (2011) The usefulness of procalcitonin and C-reactive protein as early diagnostic markers of bacteremia in cancer patients with febrile neu- tropenia. Cancer Treatment and Research, 43, 176-180.
doi:10.4143/crt.2011.43.3.176
|
[17]
|
Sakr, Y,, Sponholz, C., et al. (2008) The role of procalci- tonin in febrile neutropenic patients, review of the litera- ture. Infection, 36, 396-407.
doi:10.1007/s15010-008-7374-y
|
[18]
|
Whiting, P.F., Rutjes, A.W.S., Westwood, M.E., et al. (2011) QUADAS-2, a revised tool for the diagnostic ac- curacy studies. Annals of Internal Medicine, 155, 529- 536.
|
[19]
|
Ruokonen, E., Nousiainen, T., Pulkki, K., et al. (1999) Procalcitonin concentration in patients with neutropenic fever. European Journal of Clinical Microbiology & In- fectious Diseases, 18, 283-285.
doi:10.1007/s100960050277
|
[20]
|
Engel, A., Steinbach, G., Kern, P., et al. (1999) Diagnostic value of procalcitonin serum levels in neutropenic pa- tients with fever, comparison with interleukin-8. Scandi- navian Journal of Infectious Diseases, 31, 185-189.
doi:10.1080/003655499750006254
|
[21]
|
Giamarellos-Bourboulis, E.J., Grecka, P., Poulakou, G., et al. (2001) Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clinical Infectious Diseases, 32, 1718-1725.
doi:10.1086/320744
|
[22]
|
Jimeno, A., Garcia-Velasco, A., del Val, O., et al. (2004) Assessment of procalcitonin as a diagnostic and prognos- tic marker in patients with solid tumors and febrile neu- tropenia. Cancer, 100, 2462-2469.
doi:10.1002/cncr.20275
|
[23]
|
Giamarellou, H., Giamarellos-Bourboulis, E.J., Repoussis, P., et al. (2004) Potential use of procalcitonin as a diag- nostic criterion in febrile neutropenia, experience from a multicentre study. Clinical Microbiology and Infection, 10, 628-633. doi:10.1111/j.1469-0691.2004.00883.x
|
[24]
|
Lilienfeld-Toal, M.V., Dietrich, M.P., Glasmacher, A., et al. (2004) Markers of bacteremia in febrile neutropenic patients with hematological malignancies, procalcitonin and IL-6 are more reliable than C-reactive protein. Euro- pean Journal of Clinical Microbiology & Infectious Dis- eases, 23, 539-544. doi:10.1007/s10096-004-1156-y
|
[25]
|
Ahn, S., Lee, Y.-S., Chun, Y.H., et al. (2011) Predictive factors of bacteraemia in low-risk patients with febrile neutropenia. Emergency Medicine Journal, 29, 715-719.
|
[26]
|
Gac, A.-C., Parienti, J.-J., Chantepie, S., et al. (2011) Dy- namics of procalcitonin and bacteremia in neutropenic adults with acute myeloid leukemia. Leukemia Research, 35, 1294-1296. doi:10.1016/j.leukres.2011.05.035
|
[27]
|
Kim, D.Y., Lee, Y.-S., Ahn, S., et al. (2011) The useful- ness of procalcitonin and C-reactive protein as early di- agnostic markers of bacteremia in cancer patientswith febrile neutropenia. Cancer Research and Treatment, 43, 176-180. doi:10.4143/crt.2011.43.3.176
|
[28]
|
Rapoport, B.L. (2011) Management of the cancer patient with infection and neutropenia. Seminars in Oncology, 38, 424-430. doi:10.1053/j.seminoncol.2011.03.013
|
[29]
|
Lyman, G., Michels, S., Reynolds, M., et al. (2010) Risk of mortality in patients with cancer who experience feb- rile neutropenia. Cancer, 1, 5555-5563.
|
[30]
|
Schneider, H.-G. and Lam, Q.T. (2007) Procalcitonin for the clinical laboratory, a review. Pathology, 39, 383-390.
doi:10.1080/00313020701444564
|
[31]
|
Al-Ahwal, M., Al-Sayws, F. and Johar, I. (2005) Febrile neutronpenia comparison between solid tumors and he- matological malignincies. Arab Medical Journal, 4, 4-7.
|
[32]
|
Guyatt, G., Oxman, A., Vist, G., et al. (2008) What is quality of evidence” and why is it important to clinicians? British Medical Journal, 336, 995-998.
doi:10.1136/bmj.39490.551019.BE
|
[33]
|
Whiting, P., Weswood, M., Rutjes, A., et al. (2006) Eva- luation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Medical Research Methodology, 2006, 6, 9. doi:10.1186/1471-2288-6-9
|
[34]
|
Knudsen, T.B. and Kristiansen, T.B. (2005) Issues per- taining to data extraction and classification and publica- tion bias in meta analysis of the diagnostic accuracy of markers of bacterial infection. Clinical Infectious Dis- eases, 40, 1372-1373. doi:10.1086/429507
|
[35]
|
Whiting, P., Rutjes, A.W.S., Reitsma, J.B., et al. (2004) Sources of variation and bias in studies of diagnostic ac- curacy. Annals of Internal Medicine, 140, 189-202.
|
[36]
|
Hann, I., Viscoli, C., Paesmans, M., et al. (1997) A com- parison of outcome from febrile neutropenic episodes in children compared with adults, results from four EORTC studies. British Journal of Haematology, 99, 580-588.
doi:10.1046/j.1365-2141.1997.4453255.x
|
[37]
|
Albrich, W.C., Dusemund, F., Bucher, B., et al. (2012) Effectiveness and safety of procalcitonin-guided antibi- otic therapy in lower respiratory tract infections in “real life”. Archives of Internal Medicine, 172, 715-722.
doi:10.1001/archinternmed.2012.770
|
[38]
|
Hughes, W.T., Armstrong, D., Bodey, G.P., et al. (2002) Guidelines for the use of antimicrobial agents in neutron- penic patients with cancer. Clinical Infectious Diseases, 34, 730-751. doi:10.1086/339215
|
[39]
|
Link, H., Bohme, A., Cornely, O.A., et al. (2003) Antimi- crobial therapy of unexplained fever in neutropenic pa- tients—Guidelines of the infectious disease working par- ty of the german society of hematology and oncology. An- nals of Hematology, 82, S105-S117.
|